Search clinical trials for: Serplulimab

Total 68 results

Shanghai Changzheng Hospital

Not yet recruiting

A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

Advanced Solid Tumors With Neuroendocrine Differentiation
Shandong University

Recruiting

Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer

Cervical Cancer

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Advanced Solid Tumors

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

Esophageal Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

Extensive Stage Lung Small Cell Cancer

China
RenJi Hospital

Not yet recruiting

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Gastric Cancer | Pancreas Cancer | Biliary Tract Cancer | ESCC

China
Henan Cancer Hospital

Not yet recruiting

Serplulimab Plus Chemotherapy for Early-stage ER+/HER2- Breast Cancer

Breast Cancer

China
Peking Union Medical College Hospital

Recruiting

Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction (SNACRT)

Gastroesophageal Junction Adenocarcinoma

China
Junjie Peng

Not yet recruiting

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

Colorectal Cancer

China
RenJi Hospital
Shanghai Zhongshan Hospital

Not yet recruiting

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

First-line Treatment of Non-clear Renal Cell Carcinoma
Zhejiang Cancer Hospital

Active, not recruiting

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. (NSCLC)

Non-small Cell Lung Cancer | PDL1 Gene Mutation

China
Tianjin Medical University Cancer Institute and...

Recruiting

Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Gastric Adenocarcinoma

China
Fudan University

Recruiting

Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

Gastric Cancer

China
The First Hospital of Jilin University

Not yet recruiting

Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study

Lung Cancer
Wuhan Union Hospital, China

Not yet recruiting

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Fudan University

Recruiting

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Non-small Cell Lung Cancer | Neoadjuvant Therapy | Immunotherapy | Stage II-IIIA

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases

Colorectal Cancer | Liver Metastases

China
Yu jiren

Recruiting

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Proficient Mismatch Repair

China
Zhejiang University

Recruiting

A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

Unresectable Lung Non-Small Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer

NSCLC | Neoadjuvant Therapy

China
Henan Cancer Hospital

Not yet recruiting

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Metastatic Colon Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Limited Stage Small Cell Lung Cancer

China
The Central Hospital of Lishui City

Not yet recruiting

Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC

Carcinoma | Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

Cervical Cancer

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

Cervical Cancer

China
Tang-Du Hospital

Recruiting

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer

Gastric Cancer

China
Sun Yat-sen University

Not yet recruiting

Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

Colorectal Cancer
Zhou Chengzhi
Guangdong Provincial Hospital of Traditional Chinese Medicine; Sun Yat-sen... and other collaborators

Not yet recruiting

Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer
Sir Run Run Shaw Hospital

Not yet recruiting

First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer

Colo-rectal Cancer | Safety Issues | Efficacy, Self

China
Ruijin Hospital

Not yet recruiting

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer (NeoCHIC)

Colon Cancer

China
RenJi Hospital

Recruiting

A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

Serplulimab,Gastric Cancer, Adjuvant Therapy

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Malignant Ascites
Wuhan Union Hospital, China

Active, not recruiting

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC

Rectal Cancer

China
Fujian Cancer Hospital
Zhangzhou Municipal Hospital of Fujian Province

Recruiting

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Cervical Cancer

China
Zhejiang Cancer Hospital

Recruiting

Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (Stars)

Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

China, Japan
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

HER2-positive Gastric Cancer
Guangdong Association of Clinical Trials
Guangdong Provincial People's Hospital

Recruiting

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Small-cell Lung Cancer

China
Fujian Cancer Hospital
Hunan Cancer Hospital; Wuhan TongJi Hospital

Not yet recruiting

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Advanced Hepatocellular Carcinoma

China
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

Extensive-Stage Small Cell Lung Cancer
Fudan University

Not yet recruiting

Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C) (TORCH-C)

Locally Advanced Colon Cancer
Fujian Cancer Hospital

Not yet recruiting

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Lung Adenocarcinoma | PD-1 Inhibitor | Stage IV Non-small Cell Lung Cancer | VEGF
Peking Union Medical College Hospital

Recruiting

Serplulimab Combined With CCRT for LS-SCLC.

Small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases (SUPER BRAIN)

Bevacizumab | Brain Metastases | Immunotherapy | Non-small Cell Lung Cancer Stage II

China
Shanghai Henlius Biotech

Not yet recruiting

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Carcinoma, Hepatocellular
Second Affiliated Hospital, School of Medicine,...
Changxing People's Hospital

Recruiting

Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Unresectable Colon Cancer Peritoneal Metastases | PMMR/Ras/BRAF Wild-type

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Shanghai Henlius Biotech

Completed

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Adult Solid Tumor

China

3

Subscribe